CL2022002863A1 - Anticuerpo para receptor a de interleucina 4 humana, método de preparación y uso del mismo - Google Patents
Anticuerpo para receptor a de interleucina 4 humana, método de preparación y uso del mismoInfo
- Publication number
- CL2022002863A1 CL2022002863A1 CL2022002863A CL2022002863A CL2022002863A1 CL 2022002863 A1 CL2022002863 A1 CL 2022002863A1 CL 2022002863 A CL2022002863 A CL 2022002863A CL 2022002863 A CL2022002863 A CL 2022002863A CL 2022002863 A1 CL2022002863 A1 CL 2022002863A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- 4ralpha
- receptor
- preparation
- human interleukin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 title 1
- 102000054663 human IL4R Human genes 0.000 title 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 abstract 1
- 102000004388 Interleukin-4 Human genes 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000055229 human IL4 Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan un anticuerpo capaz de unirse a un receptor de interleucina 4 humana alfa (hIL-4Ralfa), un método de preparación para ello y un uso de este. El anticuerpo para hIL-4Ralfa se puede unir específicamente a hIL-4Ralfa, tiene buenos efectos de inhibición de la proliferación de línea celular inducida por IL-4 e IL-13, etc., y se puede utilizar para el tratamiento de enfermedades relacionadas con IL-4Ralfa, tal como enfermedades inflamatorias mediadas por el sistema inmunitario.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010309238.8A CN113527485A (zh) | 2020-04-17 | 2020-04-17 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002863A1 true CL2022002863A1 (es) | 2023-04-14 |
Family
ID=78084043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002863A CL2022002863A1 (es) | 2020-04-17 | 2022-10-17 | Anticuerpo para receptor a de interleucina 4 humana, método de preparación y uso del mismo |
Country Status (13)
Country | Link |
---|---|
US (1) | US11939387B2 (es) |
EP (1) | EP4137517A1 (es) |
JP (1) | JP7454882B2 (es) |
KR (1) | KR20230004576A (es) |
CN (2) | CN113527485A (es) |
AU (1) | AU2021255445A1 (es) |
BR (1) | BR112022021030A2 (es) |
CA (1) | CA3175786A1 (es) |
CL (1) | CL2022002863A1 (es) |
IL (1) | IL297312A (es) |
MX (1) | MX2022013034A (es) |
WO (1) | WO2021208881A1 (es) |
ZA (1) | ZA202211889B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117085122A (zh) * | 2022-04-29 | 2023-11-21 | 中山康方生物医药有限公司 | 抗人il-4ra的抗体及其用途 |
CN115353566B (zh) * | 2022-09-14 | 2023-05-09 | 江苏睿源生物技术有限公司 | 用于检测白细胞介素1-β的抗体组合及其应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
MY124565A (en) * | 1996-07-19 | 2006-06-30 | Bayer Corp | High-affinity interleukin-4-muteins |
DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
CA2543982C (en) * | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
ES2859825T3 (es) | 2006-10-02 | 2021-10-04 | Regeneron Pharma | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DK2245064T3 (da) | 2007-12-21 | 2014-10-27 | Medimmune Ltd | BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa) |
IN2014DN10408A (es) * | 2012-06-05 | 2015-08-14 | Univ Australian | |
HUE064945T2 (hu) * | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
US8980273B1 (en) * | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
NO2785538T3 (es) * | 2014-05-07 | 2018-08-04 | ||
AU2015310879A1 (en) * | 2014-09-03 | 2017-03-02 | Medimmune Limited | Stable anti-IL-4R-alpha antibody formulation |
WO2017102920A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
CN108409860B (zh) * | 2017-02-10 | 2021-10-15 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 |
CN113150146B (zh) * | 2018-02-01 | 2022-07-12 | 北京凯因科技股份有限公司 | IL-4Rα抗体及其用途 |
CN108373505B (zh) | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
CN113101364B (zh) * | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制剂的开发和应用 |
CN110872349A (zh) | 2018-09-04 | 2020-03-10 | 三生国健药业(上海)股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
US20230295312A1 (en) | 2018-12-27 | 2023-09-21 | Akeso Biopharma, Inc | Antibody against human il-4ra and use thereof |
JP2023554557A (ja) | 2020-12-22 | 2023-12-27 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗il-4r抗体又はその抗原結合断片の複合物及び医薬用途 |
-
2020
- 2020-04-17 CN CN202010309238.8A patent/CN113527485A/zh active Pending
-
2021
- 2021-04-13 CN CN202180028819.7A patent/CN115461368A/zh active Pending
- 2021-04-13 CA CA3175786A patent/CA3175786A1/en active Pending
- 2021-04-13 IL IL297312A patent/IL297312A/en unknown
- 2021-04-13 EP EP21788204.2A patent/EP4137517A1/en active Pending
- 2021-04-13 AU AU2021255445A patent/AU2021255445A1/en active Pending
- 2021-04-13 BR BR112022021030A patent/BR112022021030A2/pt unknown
- 2021-04-13 KR KR1020227039054A patent/KR20230004576A/ko active Search and Examination
- 2021-04-13 MX MX2022013034A patent/MX2022013034A/es unknown
- 2021-04-13 WO PCT/CN2021/086806 patent/WO2021208881A1/zh active Application Filing
- 2021-04-13 JP JP2022563020A patent/JP7454882B2/ja active Active
-
2022
- 2022-10-17 CL CL2022002863A patent/CL2022002863A1/es unknown
- 2022-10-17 US US18/047,039 patent/US11939387B2/en active Active
- 2022-11-01 ZA ZA2022/11889A patent/ZA202211889B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115461368A (zh) | 2022-12-09 |
US11939387B2 (en) | 2024-03-26 |
AU2021255445A1 (en) | 2022-12-08 |
CA3175786A1 (en) | 2021-10-21 |
CN113527485A (zh) | 2021-10-22 |
EP4137517A1 (en) | 2023-02-22 |
KR20230004576A (ko) | 2023-01-06 |
JP7454882B2 (ja) | 2024-03-25 |
ZA202211889B (en) | 2023-07-26 |
MX2022013034A (es) | 2022-11-09 |
IL297312A (en) | 2022-12-01 |
BR112022021030A2 (pt) | 2022-12-06 |
WO2021208881A1 (zh) | 2021-10-21 |
US20230203172A1 (en) | 2023-06-29 |
JP2023515260A (ja) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022002863A1 (es) | Anticuerpo para receptor a de interleucina 4 humana, método de preparación y uso del mismo | |
Koutsakos et al. | Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity | |
CL2008002750A1 (es) | Anticuerpo aislado que se une a al factor estimulante de colonias de granulocitos-macrofagos (gm-csf) o fragmento de union a antigeno del mismo; acido nucleico codificante; vector celular huesped; metodo de fabricacion; composicion farmaceutica que la comprende; uso para tratar o prevenir una afeccion asociada 0con gm-csf | |
AR114445A1 (es) | Conjugados de il-15, y sus usos | |
UY37635A (es) | Anticuerpos anti phf-tau y sus usos | |
BR112017008710A8 (pt) | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva | |
CL2007001335A1 (es) | Anticuerpo anti cd40; acido nucleico que lo codifica; celula; cultivo celular; metodo de produccion; composicion farmaceutica; metodo para seleccionar un anticuerpo anti cd40; y su uso para tratar sintomas de un trastorno autoinmune y/o un trastorno inflamatorio y/o para reducir el rechazo al injerto y/o para el tratamiento de cancer positivos a cd40. | |
AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
AR059604A1 (es) | Anticuerpos contra il- 22 humana y usos para los mismos | |
PE20191812A1 (es) | Compuestos y metodos para la reduccion celular especifica de tumor | |
BR112018008705A2 (pt) | método para produzir uma planta transgênica e método para produzir uma planta transformada | |
CY1117702T1 (el) | Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη | |
BR112013005145A2 (pt) | anticorpos anti-cxcl13 e métodos para seu uso | |
BRPI1014016B8 (pt) | anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos. | |
BRPI0921665A2 (pt) | humanizado anti-il-6 anticorpos | |
CL2011002417A1 (es) | Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celular huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar cancer. | |
CL2008001673A1 (es) | Dominio variable simple de la inmunoglobulina del receptor tipo 1 de la anti-interleucina 1 (il-1r1); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; antagonista de il-1r1 que lo comprende; composicion que comprende al antagonista; y uso del antagonista para tratar una condicion inflamatoria. | |
ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
CL2020002225A1 (es) | Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal | |
DOP2013000111A (es) | Anticuerpos neutralizadores anti-ccl20 | |
CO6561779A2 (es) | Anticuerpos anti-il 10- humanizados para el tratamiento de lupus sistémico eritematoso (sle) | |
BR112014026308A8 (pt) | meios de cultura celular, seu método de cultura, polipeptídeo, seu método de produção e seu uso, composições farmacêutica, e kit | |
BR112019021857A2 (pt) | Métodos e composições de célula t aperfeiçoada | |
CL2012000238A1 (es) | Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b. | |
MX2016012479A (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. |